DuraGraft vascular conduit preservation solution in patients undergoing coronary artery bypass grafting: rationale and design of a within-patient randomised multicentre trial
Open heart | 24 Apr 2018
W Ben Ali, P Voisine, PS Olsen, H Jeanmart, N Noiseux, T Goeken, V Satishchandran, F Cademartiri, G Cutter, D Veerasingam, C Brown, MY Emmert and LP Perrault
Saphenous vein grafts (SVGs) remain the most often used conduits in coronary artery bypass grafting (CABG). However, they are prone to vein graft disease (VGD) during follow-up, which may compromise clinical outcomes. Injury to the SVG endothelium during harvesting and storage promotes neointimal hyperplasia that can advance to atherosclerosis characterised by SVG failure. This trial investigates the potential benefit of DuraGraft, a novel, one-time intraoperative graft treatment developed to efficiently protect the structural and functional integrity of the vascular endothelium, on the development and progression of VGD in CABG patients.
* Data courtesy of Altmetric.com